Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban

Andexxa Approved for Reversing Anticoagulant Activity of Rivaroxaban, Apixaban  Monthly Prescribing Reference FDA approves AndexXa, first antidote for the reversal of factor Xa inhibitors  The Pharma Letter Andexxa Approved for Reversal of Factor Xa Inhibitors  Rare Disease ReportFull coverage